Why Alnylam Pharmaceuticals, Inc. Skyrocketed and Ionis Pharmaceuticals Inc Sank Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) is up more than 40% at 11:53 a.m. EDT after the company released positive phase 3 trial data for the Apollo trial testing its RNAi drug patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. Ionis Pharmaceuticals (NASDAQ: IONS) is down 9.6% because it has a competing drug, inotersen, for the same rare genetic disease.
Ironically, when Ionis released its phase 3 data in May, the same thing happened -- Alnylam went up and Ionis went down -- because Ionis' drug had some side effects and investors were anticipating Alnylam's success.
Image source: Getty Images.
Source: Fool.com
Ionis Pharmaceuticals Inc. Stock
€36.80
2.840%
Currently there is a rather positive sentiment for Ionis Pharmaceuticals Inc. with 21 Buy predictions and 5 Sell predictions.
As a result the target price of 56 € shows a very positive potential of 52.17% compared to the current price of 36.8 € for Ionis Pharmaceuticals Inc..
